Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 21, 2022

BUY
$0.46 - $0.94 $4,600 - $9,400
10,000 Added 33.33%
40,000 $21,000
Q2 2021

Jul 15, 2021

BUY
$1.04 - $1.69 $8,320 - $13,520
8,000 Added 36.36%
30,000 $36,000
Q1 2021

Jun 07, 2021

SELL
$1.32 - $3.79 $5,280 - $15,160
-4,000 Reduced 15.38%
22,000 $6,000
Q4 2020

Jan 12, 2021

SELL
$1.06 - $1.51 $10,600 - $15,100
-10,000 Reduced 27.78%
26,000 $32,000
Q1 2020

Apr 22, 2020

BUY
$0.28 - $1.23 $5,880 - $25,830
21,000 Added 140.0%
36,000 $23,000
Q4 2019

Jan 24, 2020

SELL
$0.96 - $2.94 $1,920 - $5,880
-2,000 Reduced 11.76%
15,000 $18,000
Q3 2019

Oct 10, 2019

BUY
$0.58 - $3.01 $6,380 - $33,110
11,000 Added 183.33%
17,000 $43,000
Q1 2019

Apr 17, 2019

BUY
$2.56 - $4.48 $2,560 - $4,480
1,000 Added 20.0%
6,000 $16,000
Q4 2018

Jan 14, 2019

BUY
$2.98 - $6.86 $5,960 - $13,720
2,000 Added 66.67%
5,000 $15,000
Q3 2018

Oct 05, 2018

BUY
$5.36 - $7.83 $2,680 - $3,915
500 Added 20.0%
3,000 $22,000
Q2 2018

Jul 09, 2018

BUY
$5.97 - $9.58 $2,985 - $4,790
500 Added 25.0%
2,500 $19,000
Q1 2018

Apr 09, 2018

BUY
$4.21 - $7.0 $8,420 - $14,000
2,000 New
2,000 $13,000

About T2 Biosystems, Inc.


  • Ticker TTOO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 7,050,850
  • Market Cap $15.9M
  • Description
  • T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fl...
More about TTOO
Track This Portfolio

Track Founders Capital Management Portfolio

Follow Founders Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Founders Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Founders Capital Management with notifications on news.